Symposium 2020
Update on HIV and COVID-19: Two Pandemic Infections

The HIV Cure Research Center organizes every year in September a lively symposium in the picturesque city of Ghent, Belgium. Since the pandemic outbreak of SARS-CoV-2, the lab has invested heavily in the initiation of key research in COVID19 and a symposium cannot be organized as before. Therefore, we decided to switch to a hybrid HIV-COVID19 online symposium in which we discuss key aspects of COVID19 pathogenesis and HIV cure.

We will walk you through the basic principles of COVID19 pathophysiology, animal models for COVID19 and COVID19 protection by nanobodies and a vaccine.

Latent HIV reservoir is able to refuel infection once the treatment is stopped and therefore a better understanding of both, the composition and the size of this reservoir will be important to aid the development of cure strategies as well as to monitor the efficacy of therapeutic interventions to reduce the HIV reservoir. Therefore, we will address key aspects of viral rebound and how to monitor it. Finally, we will discuss the status of HIV cure clinical trials with emphasis on novel immunotherapeutic approaches.

The HIV and COVID19 hybrid symposium will comprehensively summarizes the state of the art in COVID19 and HIV cure strategies.

Tentative program

COVID19 HOT TOPICS - Chaired by Bruno Verhasselt and Sarah Gerlo
09.00 - 09.05

Welcome and Introduction

Linos Vandekerckhove, Ghent University Hospital, Ghent, Belgium

09.05 - 09.30

Covid diseases and opportunities for immunotherapy

Bart Lambrecht, University Ghent and University Hospital Ghent, Belgium

09.30 - 09.55

Immunocorrelates of COVID19 protection

Susan Ribeiro, Case Western Reserve University, Cleveland, US

09.55 - 10.20

Vaccine development efforts at Johnson & Johnson

Hanneke Schuitemaker, Janssen Pharmaceuticals, Leiden, Netherlands

10.20 - 10.45

Break

COVID19 THERAPEUTIC APPROACHES AND SOCIETAL IMPACT - Chaired by Steven Callens and Kevin Ariën
10.45 - 11.10

Animal models for COVID19 compound and vaccine development screening

Johan Neyts, KU Leuven, Leuven, Belgium

11.10 - 11.35

Nanobodies to treat SARS-CoV-2 moving towards clinical trials

Xavier Saelens, Ghent University, Ghent, Belgium

11.35 - 12.00

Balance between COVID19 diseases and societal impact

Lieven Annemans, Professor economics of Heatlh and Wellbeing, Ghent, Belgium

12.00 - 13.00

Break/Satellite symposium

UNMASKING THE HIV VIRAL RESERVOIR - Chaired by Linos Vandekerckhove and Gilles Darcis
13.00 - 13.25

How to link clonal proliferation, intact viral sequences and viral rebound

Basiel Cole, Ghent University, Ghent, Belgium

13.25 - 13.50

Distinct viral reservoirs in individuals with spontaneous control of HIV-1

Mathias Lichterfeld, Ragon Institute, Cambridge, UK

13.50 - 14.25

Implementing intact proviral assays in clinical trials and clinical practice

Speaker TBC

14.15 - 14.30

Break

IMMUNE STRATEGIES FOR COVID19 AND HIV - Chaired by Guido Vanham
14.30 - 14.55

TCR adapted therapies to cure HIV

Lucy Dorell, University of Oxford, Oxford, UK

14.55 - 15.20

TBC

15.20 - 15.45

Current status on HIV Cure clinical trials

Linos Vandekerckhove, Ghent University, Ghent, Belgium

15.45 - 16.00

Break

16.00 - 16.15

Closing

© All rights reserved

WERELDWIJD LEVEN 37 MILJOEN MENSEN MET HIV. STEUN HET FONDS HIV ONTRAFELEN en Help hen.

Door de COVID-19 maatregelen zal de 7de editie pas in december 2021 plaatsvinden.

Bankgegevens

nl_NLDutch
en_USEnglish nl_NLDutch